Navigation Links
$13 million federal grant for research into vascular disease awarded to Weill Cornell
Date:1/16/2008

NEW YORK (Jan. 16, 2008) -- The National Heart, Lung, and Blood Institute (NHLBI) has awarded another $13 million grant to the Center of Vascular Biology at Weill Cornell Medical College in New York City for biomedical research into vascular disease -- specifically atherosclerosis and thrombosis, which are major risk factors for coronary artery disease, heart attack and stroke.

The Program Project Grant awarded to Drs. Katherine and David Hajjar represents a renewal of five ongoing projects that have already made major contributions -- elucidating the biology of cells of the artery wall, the blood cells with which they interact, and the principal cellular and genetic changes that take place in arteries that predispose them to the formation of plaque and blood clots.

The projects will continue investigations of the interactions between blood cells and vessels, testing the hypothesis that mediators -- substances including nitrogen oxides, reactive oxygen species and growth factors -- regulate blood-vessel cell activity and plaque formation, and that atherosclerosis acts like a blood clot, forming a "response to injury."

"Perhaps the greatest strength of Weill Cornell's Vascular Biology Program, which began 17 years ago, is its record of high-quality, collaborative scientific interactions and outstanding scientists who trained in this Center over the years. The complementary scientific strengths and discrete research talents of our investigators create effective research synergies and enhance the scope of our research goals," says Dr. David P. Hajjar, executive vice provost and senior executive vice dean of Weill Cornell Medical College, and dean and Frank H.T. Rhodes Distinguished Professor of Cardiovascular Biology and Genetics at Weill Cornell Graduate School of Medical Sciences.

In 1995, Weill Cornell Medical College established a Center of Vascular Biology headed by Dr. David Hajjar. Institutional funds in excess of $5 million were designated for capital improvements, equipment and faculty development to support the program.

The five NHLBI Program Project Grant projects include the following:

  • Dr. Aaron J. Marcus (Medicine) leads a study of CD39 NTPDase1. The goal is to understand the critical role of the compound as the prime regulator of blood fluidity and thrombosis.

  • Dr. Katherine A. Hajjar (Cell Biology) leads a study of the stress response in vascular cells of Annexin 2, a receptor that mediates the breakdown of a blood clot, as it relates to atherosclerosis.

  • Dr. Barbara L. Hempstead (Medicine) leads a study on the role of Brain-Derived Neurotrophic Factor (BDNF) in the promotion of blood-vessel formation in heart-attack patients.

  • Dr. Steven S. Gross (Pharmacology) leads a study of mitochondria (a kind of cellular power plant) in the function and dysfunction of eNOS (endothelial nitric oxide synthase), an enzyme that relaxes the smooth muscle in blood vessels.

  • Dr. David P. Hajjar (Biochemistry & Pathology) leads a study on the activation of the enzyme cyclooxygenase (COX) in atherosclerosis by nitrogen oxide and the impact of this activation on atherogenesis (plaque formation).

By the end of this 20-year program in 2011, it is hoped that the array of molecular links that define atherogenesis and thrombosis will have been identified.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related biology news :

1. Structure of 450 million year old protein reveals evolutions steps
2. First orchid fossil puts showy blooms at some 80 million years old
3. SyntheMed Completes $2.8 Million Equity Financing
4. Rutgers Genetics receives $7.8 million for autism research
5. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
6. UD leads $5.3-million research project on rice epigenetics
7. Rutgers high school outreach gets $3 million boost from NSF
8. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
9. UD leads $5.3-million research project on rice epigenetics
10. $22 million gift from Alfred Taubman launches new biomedical research institute
11. Nanobiosym awarded $2 million DTRA contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric ... ... DERMALOGs Face Matching enables to match face pictures ... the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... , and HILDEN, Germany , March 29, 2017 /PRNewswire/ ... FRANKFURT PRIME STANDARD: QIA) today announced the U.S. launch of ... JAK2 assay), which was cleared by the U.S. Food and Drug Administration as ... allele in genomic DNA extracted from EDTA whole blood.* ... The ipsogen JAK2 assay is processed on QIAGEN,s Rotor-Gene ...
(Date:3/29/2017)... TIKVAH, Israel , March ... (NASDAQ: BCLI), a leading developer of adult ... financial results for the year ended December ... highly successful and pivotal year for Brainstorm, with a ... made on clinical, regulatory and operational fronts," said ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing natural ... supply through enhancement of the gut microbiota, today announced the closing of its first ... New York-based Sustainable Income Capital Management, LLC and a number of private investors. The ...
Breaking Biology Technology: